Trial reportJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2014
Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women.
Trial report in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial.PloS one · 2017Trial
- Nf2 orchestrates β-arrestin2-biased PTH1R signaling to couple bone mass with skeletal integrity.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy.Bone research · 2026Review
- Teriparatide as a non-surgical salvage therapy for prolonged humerus fracture nonunion: A case report and literature review.World journal of orthopedics · 2025Article
- Parathyroid hormone-PTH1R signaling in cardiovascular disease and homeostasis.Trends in endocrinology and metabolism: TEM · 2024Review
- Osteoblast Lineage Support of Hematopoiesis in Health and Disease.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Review
- pH-Sensitive nanocarrier assisted delivery of adenosine to treat osteoporotic bone loss.Biomaterials science · 2022Article
- Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment.Journal of clinical medicine · 2022Article
- Loss of Parathyroid Hormone Receptor Signaling in Osteoprogenitors Is Associated With Accumulation of Multiple Hematopoietic Lineages in the Bone Marrow.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Review
- Review
- Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.British journal of clinical pharmacology · 2018Review
- Article
- Bone Density Loss Is Associated With Blood Cell Counts.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Observational
- New agents in HSC mobilization.International journal of hematology · 2017Review
- PTH Signaling in Osteoprogenitors Is Essential for B-Lymphocyte Differentiation and Mobilization.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Cells of the osteoblast lineage play an important role in regulating the hematopoietic stem cell (HSC) niche and early B-cell development in animal models, perhaps via parathyroid hormone (PTH)-dependent mechanisms. There are few human clinical studies investigating this phenomenon. We studied the impact of long-term daily teriparatide (PTH 1-34) treatment on cells of the hematopoietic lineage in postmenopausal women. Twenty-three postmenopausal women at high risk of fracture received teriparatide 20 mcg sc daily for 24 months as part of a prospective longitudinal trial. Whole blood measurements were obtained at baseline, 3, 6, 12, and 18 months. Flow cytometry was performed to identify hematopoietic subpopulations, including HSCs (CD34+/CD45(moderate); ISHAGE protocol) and early transitional B cells (CD19+, CD27-, IgD+, CD24[hi], CD38[hi]). Serial measurements of spine and hip bone mineral density (BMD) as well as serum P1NP, osteocalcin, and CTX were also performed. The average age of study subjects was 64 ± 5 years. We found that teriparatide treatment led to an early increase in circulating HSC number of 40% ± 14% (p = 0.004) by month 3, which persisted to month 18 before returning to near baseline by 24 months. There were no significant changes in transitional B cells or total B cells over the course of the study period. In addition, there were no differences in complete blood count profiles as quantified by standard automated flow cytometry. Interestingly, the peak increase in HSC number was inversely associated with increases in bone markers and spine BMD. Daily teriparatide treatment for osteoporosis increases circulating HSCs by 3 to 6 months in postmenopausal women. This may represent a proliferation of marrow HSCs or increased peripheral HSC mobilization. This clinical study establishes the importance of PTH in the regulation of the HSC niche within humans. © 2014 American Society for Bone and Mineral Research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.